BioCentury
ARTICLE | Top Story

Monkey wrench thrown at Introgen

February 25, 2000 8:00 AM UTC

WASHINGTON -- Introgen Therapeutics Inc., which filed last week to raise up to $92 million in an IPO, reacted with outrage on Thursday to statements by Rep. Henry Waxman (D-Calif.), who questioned the "high mortality" rate in the company's experimental gene therapy trial in lung cancer patients.

CEO David Nance said Waxman had deliberately "misrepresented the facts in a cynical effort to advance a political agenda" by challenging the number of deaths that occurred during the study, and asking whether Introgen may have been lax in reporting to federal authorities. ...